FY2027 EPS Estimates for Insulet Cut by Leerink Partnrs

Insulet Corporation (NASDAQ:PODD - Free Report) - Analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for Insulet in a report issued on Monday, July 14th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings of $7.07 per share for the year, down from their previous forecast of $7.10. The consensus estimate for Insulet's current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet's FY2028 earnings at $8.83 EPS and FY2029 earnings at $10.55 EPS.

Several other equities analysts also recently issued reports on PODD. Raymond James Financial reiterated an "outperform" rating and set a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Oppenheimer boosted their price objective on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a research report on Tuesday, May 13th. Finally, Wall Street Zen lowered Insulet from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and a consensus target price of $321.00.

Insulet Stock Performance

PODD stock traded up $1.90 during midday trading on Wednesday, reaching $285.35. The company had a trading volume of 110,549 shares, compared to its average volume of 781,384. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21. The stock has a 50 day moving average price of $309.59 and a 200 day moving average price of $280.69. Insulet has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The firm has a market capitalization of $20.08 billion, a PE ratio of 51.32, a P/E/G ratio of 2.57 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. Insulet's quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.73 earnings per share.

Insider Buying and Selling at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president directly owned 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.39% of the company's stock.

Hedge Funds Weigh In On Insulet

A number of hedge funds have recently modified their holdings of the stock. Norges Bank bought a new stake in Insulet in the fourth quarter worth $248,806,000. GAMMA Investing LLC lifted its position in Insulet by 27,298.6% during the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after buying an additional 661,717 shares in the last quarter. American Century Companies Inc. grew its holdings in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after acquiring an additional 297,734 shares during the last quarter. Nuveen LLC bought a new stake in Insulet during the 1st quarter worth about $74,163,000. Finally, Kayne Anderson Rudnick Investment Management LLC increased its holdings in shares of Insulet by 1,316.5% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier's stock valued at $50,818,000 after purchasing an additional 179,850 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.